Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Segment information is as follows (in thousands):

	Year Ended December 31, 2022
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product revenue	$	116,676	$	—	$	116,676
Research and development revenue	9,936		11,978		21,914
Total revenues	$	126,612	$	11,978	$	138,590
Primary geographical markets:
Americas	$	12,089	$	4,911	$	17,000
EMEA	49,473		7,067		56,540
APAC	65,050		—		65,050
Total revenues	$	126,612	$	11,978	$	138,590

	Year Ended December 31, 2021
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product revenue	$	70,657	$	—	$	70,657
Research and development revenue	19,858		14,239		34,097
Total revenues	$	90,515	$	14,239	$	104,754
Primary geographical markets:
Americas	$	16,114	$	7,367	$	23,481
EMEA	13,315		6,872		20,187
APAC	61,086		—		61,086
Total revenues	$	90,515	$	14,239	$	104,754

	Year Ended December 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product revenue	$	30,220	$	—	$	30,220
Research and development revenue	17,886		20,950		38,836
Total revenues	$	48,106	$	20,950	$	69,056
Primary geographical markets:
Americas	$	11,111	$	13,241	$	24,352
EMEA	11,548		7,709		19,257
APAC	25,447		—		25,447
Total revenues	$	48,106	$	20,950	$	69,056

Contract Balances

The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):

	December 31, 2022		December 31, 2021
Contract assets	$	2,116	$	4,557
Unbilled receivables	$	7,016	$	8,558
Contract costs	$	19	$	56
Contract liabilities: deferred revenue	$	30,609	$	6,335

Contract with Customer

We recognized the following revenues (in thousands):

	Year Ended December 31,
Revenue recognized in the period for:	2022		2021
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied	$	2,038	$	1,858
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	279		7,645
Performance obligations satisfied from new activities in the period - contract revenue	136,273		95,251
Total revenues	$	138,590	$	104,754

Performance Obligation, Expected Timing of Satisfaction

The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands):

	2023		2024		2025		2026 and Thereafter		Total
Product revenue	$	12,136	$	13,080	$	140	$	3,640	$	28,996
Research and development revenue	1,592		21		—		—		1,613
Total revenues	$	13,728	$	13,101	$	140	$	3,640	$	30,609